Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Tg Therapeutics (TGTX) over the last 5 years, with Q3 2025 value amounting to $3.3 million.

  • Tg Therapeutics' Other Non Operating Income rose 2246.81% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year increase of 9886.14%. This contributed to the annual value of $7.7 million for FY2024, which is 5251.78% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Other Non Operating Income is $3.3 million, which was up 2246.81% from $2.8 million recorded in Q2 2025.
  • Tg Therapeutics' Other Non Operating Income's 5-year high stood at $3.6 million during Q1 2025, with a 5-year trough of $604000.0 in Q1 2023.
  • Over the past 4 years, Tg Therapeutics' median Other Non Operating Income value was $1.9 million (recorded in 2022), while the average stood at $1.9 million.
  • As far as peak fluctuations go, Tg Therapeutics' Other Non Operating Income tumbled by 5388.6% in 2023, and later soared by 30943.18% in 2025.
  • Over the past 4 years, Tg Therapeutics' Other Non Operating Income (Quarter) stood at $1.9 million in 2022, then plummeted by 53.89% to $890000.0 in 2023, then surged by 188.2% to $2.6 million in 2024, then increased by 27.29% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $2.8 million for Q2 2025, and $3.6 million during Q1 2025.